4.4 Review

Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy

期刊

出版社

SPRINGER
DOI: 10.1007/s11864-021-00847-y

关键词

Head and neck; Proton therapy; De-intensification; Oropharyngeal cancer; Clinical trials; De-escalation

类别

向作者/读者索取更多资源

The rise in HPV-associated OPC, diagnosed at a young age with a good prognosis, has led to the need for treatment techniques like IMPT, which reduce side effects. Preclinical studies show that HPV-positive squamous cell carcinoma is more sensitive to proton radiation. Retrospective studies suggest that IMPT has lower rates of side effects compared to intensity-modulated photon radiotherapy. Two phase III trials are expected to provide evidence on the effectiveness of IMPT for these patients.
Opinion statement The rise in the incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPC), the relatively young age at which it is diagnosed, and its favorable prognosis necessitate the use of treatment techniques that reduce the likelihood of side effects during and after curative treatment. Intensity-modulated proton therapy (IMPT) is a form of radiotherapy that de-intensifies treatment through dose de-escalation to normal tissues without compromising dose to the primary tumor and involved, regional lymph nodes. Preclinical studies have demonstrated that HPV-positive squamous cell carcinoma is more sensitive to proton radiation than is HPV-negative squamous cell carcinoma. Retrospective studies comparing intensity-modulated photon (X-ray) radiotherapy to IMPT for OPC suggest comparable rates of disease control and lower rates of pain, xerostomia, dysphagia, dysgeusia, gastrostomy tube dependence, and osteoradionecrosis with IMPT-all of which meaningfully affect the quality of life of patients treated for HPV-associated OPC. Two phase III trials currently underway-the Randomized Trial of IMPT versus IMRT for the Treatment of Oropharyngeal Cancer of the Head and Neck and the TOxicity Reduction using Proton bEam therapy for Oropharyngeal cancer (TORPEdO) trial-are expected to provide prospective, level I evidence regarding the effectiveness of IMPT for such patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据